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Abstract 
An extensive literature search to identify and collect all relevant literature on the oral toxicity of furan 
and its methyl analogues, 2-methylfuran and 3-methylfuran was performed in the two databases 
PubMed and Web of Science for four Areas. The literature search resulted for Area 1 (toxicokinetics) in 
1,674 hits from PubMed and 2,318 hits from Web of Science; for Area 2 (oral toxicity in experimental 
animals) in 2,329 hits from PubMed and 3,914 hits from Web of Science; for Area 3 (in vitro and in 
vivo genotoxicity and mode of action) in 1,100 hits from PubMed and 2,290 hits from Web of Science; 
and for Area 4 (observations in humans) in 639 hits from PubMed and 1,073 from Web of Science. 
After removal of the duplicates, the total number of hits for Area 1 was 3,184, for Area 2 was 4,883, 
for Area 3 was 2,588, and for Area 4 was 1,295. The evaluation of all retrieved references for 
relevance by screening the title and abstract (if available) and applying eligibility criteria 
(inclusion/exclusion) resulted in a total number of relevant references for Area 1 of 33, for Area 2 of 
44, for Area 3 of 75 (including two relevant references located in the Area 2 literature search), and for 
Area 4 of 5.  
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Summary 
The overall aim of this assignment was to identify and collect all relevant literature on the oral toxicity 
of furan and its methyl analogues, 2-methylfuran and 3-methylfuran to support preparatory work for 
the human risk assessment of these substances. 
Initially, four tailored search strings were designed to retrieve all potentially relevant studies for the 
hazard identification and characterisation of furan and its methyl analogues. The four tailored search 
strings covered the following four areas: 
 Area 1: Data on toxicokinetics (absorption, distribution, metabolism and excretion (ADME)) in 
experimental animals and humans and from in vitro studies. 
 Area 2: Data on oral toxicity in experimental animals. 
 Area 3: Data on in vitro and in vivo genotoxicity and mode of action (MoA). 
 Area 4: Data on observations in humans (including epidemiological studies, case reports and 
biomarkers of exposure). 
The search strings were tailored to the databases PubMed and Web of Science and consisted of two 
major steps each designed to search titles and abstracts in PubMed and Web of Science, as well as 
full text in PubMed. Combinations of search terms were used, starting with a broad search for each 
compound (furan, 2-methylfuran and 3-methylfuran) and its synonyms (step 1) and followed by an 
Area specific step with the addition of search terms relevant to each Area (step 2). 
Then the four tailored search strings were employed to retrieve all relevant studies from the two 
databases. Data published since 1990 were retrieved for Area 1-3 and since 2004 for Area 4. All 
retrieved references were exported as separate files into EndNoteTM. Duplicate studies were then 
removed after combining the two EndNoteTM files per Area into one single combined file per Area. 
The literature search resulted for Area 1 in 1,674 hits from PubMed and 2,318 hits from Web of 
Science; for Area 2 in 2,329 hits from PubMed and 3914 hits from Web of Science; for Area 3 in 1,100 
hits from PubMed and 2,290 hits from Web of Science; and for Area 4 in 639 hits from PubMed and 
1,073 from Web of Science. After removal of the duplicates, the total number of hits for Area 1 was 
3,184, for Area 2 was 4,883, for Area 3 was 2,588, and for Area 4 was 1,295. 
All retrieved references were then evaluated for relevance by applying eligibility criteria 
(inclusion/exclusion). The selection for relevance was conducted by screening the title and abstract (if 
available) and all the retrieved references were ultimately sorted into one of the following two 
categories: 
 Relevant to the research objectives: References ultimately evaluated to be relevant were 
included in this category. In case the relevance could not be evaluated because e.g. of 
missing or vague abstracts individual full texts were obtained if possible to evaluate if the 
study was truly relevant. If relevance remained uncertain, the references were also included 
in this category, as a conservative approach. 
 Not relevant to the research objectives: References ultimately evaluated not to be in-scope 
were included in this category. 
The results of the reference selection process were reported in summary tables (Excel files), one table 
per Area. The summary tables include all pertinent information for each of the references in the 
‘Relevant’ category as identified by the eligibility criteria and which could be retrieved from the title 
and abstract (when available). The summary tables also include references in the ‘Not relevant’ 
category, including the reason for exclusion, but without any study details.  
The evaluation for relevance resulted in a total number of relevant references for Area 1 of 33, for 
Area 2 of 44, for Area 3 of 75 (including two relevant references located in the Area 2 literature 
search), and for Area 4 of 5.  
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1. Introduction  
 Background and Terms of Reference as provided by the requestor 1.1.
This contract was awarded by EFSA to: 
Contractor: National Food Institute, Technical University of Denmark 
Contract title: Identifying and collecting relevant literature related to the oral toxicity of furan and its 
methyl analogues, 2-methylfuran and 3-methylfuran 
Contract number: RC/EFSA/BIOCONTAM/2016/02 
1.1.1. Background as provided by EFSA 
The Unit on Biological Hazard and Contaminants (BIOCONTAM Unit) supports the Panel on 
Contaminants in the Food Chain (CONTAM Panel), which provides scientific advice on contaminants in 
the food chain and undesirable substances such as natural toxicants, mycotoxins and residues of 
unauthorised substances.  
In January 2016 EFSA received a mandate from the European Commission for a scientific opinion on 
the health risks related to the presence of furan and its methyl analogues in food. The mandate was 
allocated to the CONTAM Panel. A Working Group will be established to develop the draft opinion.  
To support preparatory work for the hazard identification and characterization steps in the human risk 
assessment, EFSA wishes to outsource an extensive literature search (ELS) related to the toxicity of 
furan and its methyl analogues, 2-methylfuran and 3-methylfuran.  
The contractor should ensure that all the steps for conducting the ELS are properly documented and 
reported.  
The present Call is based on EFSA’s 2016 Work Programme for Grants and operational Procurements 
Financing Decision found in Annex II of the Programming Document 2016-2018, available on the 
EFSA’s website1. 
1.1.2. Objectives as provided by EFSA 
The overall aim of the assignment is to identify and collect all relevant literature on the oral toxicity of 
furan and its methyl analogues, 2-methylfuran and 3-methylfuran to support preparatory work for the 
human risk assessment of these substances. 
The three specific objectives in this assignment include: 
Objective 1: 
To design four tailored search strategies to retrieve all potentially relevant studies for the hazard 
identification and characterisation of furan and its methyl analogues, 2-methylfuran and 3-
methylfuran. The four tailored search strategies will cover the following four areas: 
 Area 1: Data on toxicokinetics (absorption, distribution, metabolism and excretion (ADME)) in 
experimental animals and humans and from in vitro studies. 
 Area 2: Data on oral toxicity in experimental animals. 
 Area 3: Data on in vitro and in vivo genotoxicity and mode of action (MoA). 
 Area 4: Data on observations in humans (including epidemiological studies, case reports and 
biomarkers of exposure). 
 
                                                          
1 http://www.efsa.europa.eu/sites/default/files/mb151203-a2.pdf 
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Objective 2: 
To retrieve all potentially relevant studies for the hazard identification and characterisation of furan 
and its methyl analogues, 2-methylfuran and 3-methylfuran by execution of four extensive literature 
searches (ELSs) using the tailored search strings for the four areas developed under objective 1. 
Objective 3: 
To determine the relevance of the retrieved studies by screening titles and abstracts according to 
preselected eligibility criteria and prepare the outcome of the project for presentation to EFSA. 
 
2. Methodologies  
The methodology for systematic reviews including guidance for development and optimisation of a 
search strategy and for selecting relevant studies has been described by EFSA (2010). This 
methodology has been implemented as appropriate in the Tasks described below.   
 Objective 1 2.1.
2.1.1. Task 1 Developing tailored search strategies and search strings for 
collecting relevant studies 
Four tailored search strings on the four areas described below were developed for identifying all 
potentially relevant studies for the risk assessment of furan and its methyl analogues, 2-methylfuran 
and 3-methylfuran.  
The four search strings are driven by the eligibility criteria for each Area (1-4) as provided by EFSA in 
the technical specifications which are copied in Appendix A of this external report. The search strings 
were tailored to the databases PubMed and Web of Science2. They consisted of two major steps each 
designed to search titles and abstracts in PubMed and Web of Science, as well as full text in PubMed. 
Combinations of search terms were used, starting with a broad search for each compound (furan, 2-
methylfuran and 3-methylfuran) and its synonyms (step 1). The next step was Area specific with the 
addition of search terms relevant to each Area (step 2). The eligibility criteria contained both inclusion 
and exclusion criteria. Use of the Boolean operator “NOT” was avoided as a relevant reference can 
contain discussions on both relevant and excluded search terms. Instead exclusion criteria such as 
language (only English) and publication type (only peer reviewed primary research studies, systematic 
reviews and meta-analyses) were implemented in the search strategy.   
Step 1 was designed to capture titles and abstracts in PubMed and Web of Science, as well as full text 
in PubMed containing furan, 2-methylfuran or 3-methylfuran. This step included compound name and 
synonyms, e.g. for furan:  
 Furan  
 OR Divinylene oxide  
 OR Furfuran 
 OR Oxacyclopentadiene 
 OR Oxole 
 OR Tetrole 
 OR … 
                                                          
2 Including the following databases: Web of ScienceTM Core Collection, BIOSIS Citation IndexSM, CABI: CAB Abstracts®, 
Current Contents Connect®, Data Citation index SM, FSTA®- the food science resource, MEDLINE®, SciELO Citation Index 
and Zoological Recored®. 
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“OR” is a Boolean operator that expands the amount of references returned when used in a search 
string as just one of the search terms need to be present in the returned references. 
Step 2 was designed to capture titles and abstracts in PubMed and Web of Science, as well as full text 
in PubMed containing Area specific search terms. This step could for Area 2 include: 
 Oral  
 OR gavage 
 OR feed 
 OR liver 
 OR hepato* 
 OR cancer 
 OR carcino* 
 OR … 
“*” symbolises truncation and is used for finding singular and plural forms of words and various 
endings. Both PubMed and Web of Science use an asterisk as their truncation symbol. 
Search terms were identified in collaboration with the entire project team to identify as many as 
possible. The search terms were combined and tested in the two databases to develop the most 
sensitive and appropriate search string.  
The search strings were also tested by assessing whether it retrieved relevant papers already known 
to the project team (e.g. (Moser et al., 2009; Gill et al., 2010; Terrell et al., 2014; Churchwell et al., 
2015)) as recommend in EFSA (2010).  
 Objective 2 2.2.
2.2.1. Task 2 Execution of four extensive literature searches using the tailored 
search strings developed in task 1 
The four tailored search strings developed in Task 1 and agreed upon by EFSA were employed to 
retrieve all relevant studies from the databases PubMed and Web of Science on furan and its methyl 
analogues, 2-methylfuran and 3-methylfuran.  
Data published since 1990 were retrieved on toxicokinetics (ADME) in experimental animals, humans 
and in vitro (Area 1), oral toxicity in experimental animals (Area 2) and in vitro and in vivo 
genotoxicity and mode of action (Area 3). Data published since 2004 were retrieved on observations 
in humans (including epidemiological studies, case reports, biomarkers of exposure) (Area 4). 
All references located in the extensive literature searches in PubMed and Web of Science were 
exported as separate files into EndNoteTM. Title, author, journal, year of publication and abstract were 
included for each study imported to EndNoteTM and the number of hits resulting from each of the four 
tailored search strings in each of the two databases were recorded in a log file. Duplicate studies were 
then removed after combining the two EndNoteTM files per Area into one single combined file per 
Area. 
 Objective 3 2.3.
2.3.1. Task 3 Selection of all relevant studies retrieved by the extensive 
literature searches 
All studies retrieved by the extensive literature searches and imported into the combined EndNoteTM 
files, one file per Area (Task 2), were evaluated for relevance by applying eligibility criteria 
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(inclusion/exclusion) as described by EFSA in the technical specifications (see Appendix A of this 
external report) for each subject Area (1-4). The selection for relevance was conducted by screening 
the title and abstract (if available) and all the retrieved studies were ultimately sorted into one of the 
following two categories: 
 Relevant to the research objectives: References ultimately evaluated to be relevant were 
included in this category. In case the relevance could not be evaluated because e.g. of 
missing or vague abstracts individual full texts were obtained if possible to evaluate if the 
study was truly relevant, as recommended by EFSA (2010). If relevance remained uncertain, 
the references were also included in this category, as a conservative approach. 
 Not relevant to the research objectives: References ultimately evaluated not to be in-scope 
were included in this category. 
To ensure a uniform understanding of the eligibility criteria in the four Areas, these were discussed in 
an internal meeting before all references were assessed for relevance. 
According to the original protocol proposed by the Contractor, “Each will be individually assessed by 
two reviewers in order to prevent the introduction of errors and personal bias. In the possible event of 
disagreements between reviewers a third member of the project team will assist in solving the specific 
issue as recommended by EFSA (2010).” However, as a result of the very broad search strings for 
each Area, a huge number of irrelevant hits were retrieved in the ELS for each Area. It was therefore 
decided that one principal team member for each Area performed an initial sorting of the hits into one 
of the following three categories: 1) Relevant, 2) possibly relevant, and 3) not relevant. All the 
references considered as possibly relevant were then assessed by another principal team member for 
each Area and the references were included either in the ‘Relevant’ category or in the ‘Not relevant’ 
category. The project coordinator also assisted in the evaluation of the possibly relevant references. 
In case relevance still remained uncertain, the references were included in the ‘Relevant’ category, as 
a conservative approach.  
This deviation from the original protocol is not considered to invalidate the outcome of the selection 
for relevance of the studies retrieved from the ELSs as both the principal team members for each Area 
have an extensive experience within the specific Area and as the project coordinator has an extensive 
experience within all four Areas.  
The results of the reference selection process were reported in summary tables, one table per Area. 
The information included in the summary tables ensures that all eligibility criteria of the studies were 
considered. Additional fields for relevance (answered by yes/no based on the eligibility criteria), the 
person(s) responsible for the screening and comments were also included in the summary tables.   
To ensure a uniform reporting in the four summary tables, five representative references within each 
Area were assessed by all principal team members and discussed in an internal meeting before all 
references were reported in the summary tables.  
2.3.2. Task 4 Preparation of EndNoteTM files, summary tables and reference lists 
EndNoteTM files 
All references found relevant for the risk assessment of furan and its methyl analogues, 2-methylfuran 
and 3-methylfuran within Area 1-4 were collected in a single EndNoteTM file including all indexed fields 
per reference (i.e. title, author, publication year, journal and abstract). 
Summary tables 
Summary tables (Excel files) were prepared, one table for each Area.  
Reference lists 
All relevant references were collected in a reference list (see Appendix B).  
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3. Results 
 Objective 1 3.1.
3.1.1. Task 1 Developing tailored search strategies and search strings for 
collecting relevant studies 
The search strings that resulted in the largest number of potentially relevant studies on furan and its 
methyl analogues, 2-methylfuran and 3-methylfuran within Area 1-4 were submitted to EFSA on 8 
April 2016 (email) as part of Deliverable 1. The proposed search strings were discussed with EFSA at 
the kick-off meeting on 11 April, revised and agreed on 15 April (email). The agreed search strings for 
Area 1-4 are presented below. 
In the proposed search strings, “OR” is the Boolean operator that expands the amount of references 
returned when used in a search string as just one of the search terms need to be present in the 
returned references. “*” symbolises truncation and is used for finding singular and plural forms of 
words and various endings. Both PubMed and Web of Science use an asterisk as their truncation 
symbol. 
Step 1: 
The search strings agreed for step 1 are as follows: 
Furan: 
(Furan OR Furane OR Furfuran OR Furfurane OR Tetrole) 
2-Methylfuran: 
(2-Methylfuran OR 2-Methylfurane OR 5-Methylfuran OR 5-Methylfurane OR Silvan OR Sylvan) 
3-Methylfuran: 
(3-Methylfuran OR 3-Methylfurane) 
Step 2: 
The Area specific search strings agreed for step 2 are as follows: 
Area 1: Data on toxicokinetics (ADME) in experimental animals and humans and from in vitro studies. 
(Furan OR Furane OR Furfuran OR Furfurane OR Tetrole OR Silvan OR Sylvan OR 2-Methylfuran OR 2-
Methylfurane OR 3-Methylfuran OR 3-Methylfurane OR 5-Methylfuran OR 5-Methylfurane) AND 
(absor* OR tissue* OR metaboli* OR excret* OR kinetic* OR toxicokinetic* OR pharmacokinetic* OR 
degrad* OR biotrans*) 
Area 2: Data on oral toxicity in experimental animals. 
(Furan OR Furane OR Furfuran OR Furfurane OR Tetrole OR Silvan OR Sylvan OR 2-Methylfuran OR 2-
Methylfurane OR 3-Methylfuran OR 3-Methylfurane OR 5-Methylfuran OR 5-Methylfurane) AND (oral 
OR diet* OR gavage OR feed OR food OR organ* OR tissue* OR cancer* OR carcino* OR tumor* OR 
tumour* OR tox* OR immun* OR teratogen* OR rat OR mouse OR mice OR rabbit*) 
Area 3: Data on in vitro and in vivo genotoxicity and MoA. 
(Furan OR Furane OR Furfuran OR Furfurane OR Tetrole OR Silvan OR Sylvan OR 2-Methylfuran OR 2-
Methylfurane OR 3-Methylfuran OR 3-Methylfurane OR 5-Methylfuran OR 5-Methylfurane) AND 
(genotox* OR mode OR action OR mechanism* OR muta* OR DNA OR damage OR repair OR 
clastogen* OR aneugen* OR chromosom*) 
Area 4: Data on observations in humans (including epidemiological studies, case reports and 
biomarkers of exposure). 
(Furan OR Furane OR Furfuran OR Furfurane OR Tetrole OR Silvan OR Sylvan OR 2-Methylfuran OR 2-
Methylfurane OR 3-Methylfuran OR 3-Methylfurane OR 5-Methylfuran OR 5-Methylfurane) AND 
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(epidemio* OR biomarker* OR exposure* OR case* OR poison* OR cohort* OR cross-sectional OR 
random* OR work*) 
 Objective 2 3.2.
3.2.1. Task 2 Execution of four extensive literature searches using the tailored 
search strings developed in task 1 
The number of hits resulting from each of the four tailored search strings in each of the two 
databases PubMed and Web of Science were recorded in a log file: 
 
OBJECTIVE: Log file for the four tailored search strings to retrieve all relevant data on furan and its methyl 
analogues, 2-methylfuran and 3-methylfuran. 
Date of 
search 
Substance 
name 
Databases & 
Search Engines  
Search terms  Limitations 
applied to 
search 
No of 
'hits' 
Comments & 
follow-up 
actions 
April 14, 
2016 
Furan PubMed (Furan OR furane OR 
furfuran OR furfurane 
OR tetrole OR silvan 
OR sylvan OR 2-
methylfuran OR 2-
methylfurane OR 3-
methylfuran OR 3-
methylfurane OR 5-
methylfuran OR 5-
methylfurane) AND 
(absor* OR tissue* 
OR metaboli* OR 
excret* OR kinetic* 
OR toxicokinetic* OR 
pharmacokinetic* OR 
degrad* OR 
biotrans*) 
Year: 1990- 
Language: 
English 
1,674 AREA 1 
 
Has been 
exported to 
EndNoteTM 
April 14, 
2016 
Furan PubMed (Furan OR furane OR 
furfuran OR furfurane 
OR tetrole OR silvan 
OR sylvan OR 2-
methylfuran OR 2-
methylfurane OR 3-
methylfuran OR 3-
methylfurane OR 5-
methylfuran OR 5-
methylfurane) AND 
(oral OR diet* OR 
gavage OR feed OR 
food OR organ* OR 
tissue* OR cancer* 
OR carcino* OR 
tumor* OR tumour* 
OR tox* OR rat OR 
mouse OR mice OR 
rabbit* OR immun* 
OR teratogen*) 
Year: 1990- 
Language: 
English 
2,329 AREA 2 
 
Has been 
exported to 
EndNoteTM 
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Date of 
search 
Substance 
name 
Databases & 
Search Engines  
Search terms  Limitations 
applied to 
search 
No of 
'hits' 
Comments & 
follow-up 
actions 
April 14, 
2016 
Furan PubMed (Furan OR furane OR 
furfuran OR furfurane 
OR tetrole OR silvan 
OR sylvan OR 2-
methylfuran OR 2-
methylfurane OR 3-
methylfuran OR 3-
methylfurane OR 5-
methylfuran OR 5-
methylfurane) AND 
(genotox* OR mode 
OR action OR 
mechanism* OR 
muta* OR DNA OR 
damage OR repair OR 
clastogen* OR 
aneugen* OR 
chromosom*) 
Year: 1990- 
Language: 
English 
1,100 AREA 3 
 
Has been 
exported to 
EndNoteTM 
April 14, 
2016 
Furan PubMed (Furan OR furane OR 
furfuran OR furfurane 
OR tetrole OR silvan 
OR sylvan OR 2-
methylfuran OR 2-
methylfurane OR 3-
methylfuran OR 3-
methylfurane OR 5-
methylfuran OR 5-
methylfurane) AND 
(epidemio* OR 
biomarker* OR 
exposure* OR case* 
OR poison* OR 
cohort* OR cross-
sectional OR random* 
OR work*) 
Year: 2004- 
Language: 
English 
639  AREA 4 
 
Has been 
exported to 
EndNoteTM 
April 18, 
2016 
Furan Web of Science (Furan OR furane OR 
furfuran OR furfurane 
OR tetrole OR silvan 
OR sylvan OR 2-
methylfuran OR 2-
methylfurane OR 3-
methylfuran OR 3-
methylfurane OR 5-
methylfuran OR 5-
methylfurane) AND 
(absor* OR tissue* 
OR metaboli* OR 
excret* OR kinetic* 
OR toxicokinetic* OR 
pharmacokinetic* OR 
degrad* OR 
biotrans*) 
Year: 1990- 
Language: 
English 
2,318 AREA 1 
 
Has been 
exported to 
EndNoteTM 
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Date of 
search 
Substance 
name 
Databases & 
Search Engines  
Search terms  Limitations 
applied to 
search 
No of 
'hits' 
Comments & 
follow-up 
actions 
April 18, 
2016 
Furan Web of Science (Furan OR furane OR 
furfuran OR furfurane 
OR tetrole OR silvan 
OR sylvan OR 2-
methylfuran OR 2-
methylfurane OR 3-
methylfuran OR 3-
methylfurane OR 5-
methylfuran OR 5-
methylfurane) AND 
(oral OR diet* OR 
gavage OR feed OR 
food OR organ* OR 
tissue* OR cancer* 
OR carcino* OR 
tumor* OR tumour* 
OR tox* OR rat OR 
mouse OR mice OR 
rabbit* OR immun* 
OR teratogen*) 
Year: 1990- 
Language: 
English 
3,914 AREA 2 
 
Has been 
exported to 
EndNoteTM 
April 18, 
2016 
Furan Web of Science (Furan OR furane OR 
furfuran OR furfurane 
OR tetrole OR silvan 
OR sylvan OR 2-
methylfuran OR 2-
methylfurane OR 3-
methylfuran OR 3-
methylfurane OR 5-
methylfuran OR 5-
methylfurane) AND 
(genotox* OR mode 
OR action OR 
mechanism* OR 
muta* OR DNA OR 
damage OR repair OR 
clastogen* OR 
aneugen* OR 
chromosom*) 
Year: 1990- 
Language: 
English 
2,290 AREA 3 
 
Has been 
exported to 
EndNoteTM 
April 18, 
2016 
Furan Web of Science (Furan OR furane OR 
furfuran OR furfurane 
OR tetrole OR silvan 
OR sylvan OR 2-
methylfuran OR 2-
methylfurane OR 3-
methylfuran OR 3-
methylfurane OR 5-
methylfuran OR 5-
methylfurane) AND 
(epidemio* OR 
biomarker* OR 
exposure* OR case* 
OR poison* OR 
cohort* OR cross-
sectional OR random* 
OR work*) 
Year: 2004- 
Language: 
English 
1,073 AREA 4 
 
Has been 
exported to 
EndNoteTM 
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For Area 1, 1,674 hits resulted from the ELS in PubMed and 2,318 hits in Web of Science. For Area 2, 
2,329 hits resulted from the ELS in PubMed and 3,914 hits in Web of Science. For Area 3, 1,100 hits 
resulted from the ELS in PubMed and 2,290 hits in Web of Science. For Area 4, 639 hits resulted from 
the ELS in PubMed and 1,073 hits in Web of Science.  
After removal of the duplicates, the total number of hits for Area 1 was 3,184, for Area 2 was 4,883, 
for Area 3 was 2,588, and for Area 4 was 1,295. 
The results of the ELS and an initial selection of potentially relevant studies on furan and its methyl 
analogues, 2-methylfuran and 3-methylfuran for Area 1-4 were submitted to EFSA on 11 May (emails) 
as Deliverable 2 and then uploaded to the DMS on 13 May. 
For each of Area 1-4, three EndNote files were submitted: one including all hits from PubMed (named: 
My EndNote Library_AREA X_PubMed.enlx), one including all hits from Web of Science (named: My 
EndNote Library_AREA X_Web of Science.enlx), and one including the combined hits from PubMed 
and Web of Science with duplicate records removed (named: My EndNote Library_AREA X.enlx). 
In the combined EndNote files, one file per Area, all hits were separated into 4 folders and named as 
follows:  
 ‘Relevant’: Containing hits initially evaluated to be of relevance for this procurement 
 ‘Maybe relevant’: Containing hits where relevance initially was considered uncertain, as a 
conservative approach. Hits in this folder were afterwards sorted into either the ‘relevant’ or 
‘not relevant’ following further scrutiny before submission of the draft final deliverable. 
 ‘Not relevant’: Containing hits initially evaluated not to be in-scope for this procurement 
 ‘Trash’: Containing the removed duplicates 
For Area 2 a 5th folder contained 3 hits initially considered of relevance for Area 3; these were further 
scrutinized before submission of the draft final deliverable. 
 Objective 3 3.3.
3.3.1. Task 3 Selection of all relevant studies retrieved by the extensive 
literature searches 
A proposal for the information to be included in the summary tables for each area (Excel file) was 
submitted to EFSA on 8 April (email) as part of Deliverable 1. The proposed summary tables were 
discussed with EFSA at the kick-off meeting on 11 April. EFSA had a number of suggestions for 
revisions which were agreed and reflected in the revised version of the summary tables submitted to 
EFSA on 15 April (email).  
According to the tender specifications, the summary tables should only include the relevant studies. 
However, for transparency reasons, it was agreed at the kick-off meeting also to include the non-
relevant studies (including the reason for exclusion), but without any study details. 
The total number of relevant references for Area 1 was 33, for Area 2 44, for Area 3 75 (including two 
relevant references located in the Area 2 literature search), and for Area 4 5. 
3.3.2. Task 4 Preparation of EndNoteTM files, summary tables and reference lists 
The EndNoteTM files, the summary tables and the reference lists were submitted to EFSA on 31 May 
(uploaded to the DMS) as part of the draft final deliverable.  
The final protocol and project plan implemented by the Contractor to carry out the project was also 
submitted to EFSA on 31 May (uploaded to the DMS and by email) as part of the draft final 
deliverable. 
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EndNoteTM files 
For each of Area 1-4, three EndNote files were submitted: One file per Area including all hits from 
PubMed (named: My EndNote Library_AREA X_PubMed.enlx) which are identical to the files submitted 
as part of Deliverable 2; one file per Area including all hits from Web of Science (named: My EndNote 
Library_AREA X_Web of Science.enlx) which are identical to the files submitted as part of Deliverable 
2; and one file per Area including the combined hits from PubMed and Web of Science (named: My 
EndNote Library_AREA X_deliverable 3.enlx). 
In the combined EndNote files, one file per Area, all hits were separated into 2 folders and named as 
follows:  
 ‘Relevant’: Containing all the references evaluated to be of relevance for the research 
objectives, including the references of uncertain relevance 
 ‘Not relevant’: Containing all the references evaluated not to be in-scope for the research 
objectives 
For Area 2, a 3rd folder contains hits of relevance for Area 3. 
Summary tables 
Summary tables (Excel files) were prepared, one table for each Area 1-4. The summary tables include 
all pertinent information for each of the references in the ‘Relevant’ category as identified by the 
eligibility criteria described by EFSA in the technical specifications (see Appendix A of this external 
report) which could be retrieved from the title and abstract (when available). The summary tables also 
include references in the ‘Not relevant’ category, including the reason for exclusion, but without any 
study details. All references included in the ‘Relevant’ category appear on a green background; all 
references included in the ‘Not relevant’ category appear on a white background.  
Reference lists 
All relevant references were collected in a reference list (Word file), one file per Area. The reference 
lists are included in Appendix B. 
 
4. Conclusions 
An extensive literature search to identify and collect all relevant literature on the oral toxicity of furan 
and its methyl analogues, 2-methylfuran and 3-methylfuran was performed in the two databases, 
PubMed and Web of Science, for four Areas.  
The literature search resulted for Area 1 (toxicokinetics) in 1,674 hits from PubMed and 2,318 hits 
from Web of Science; for Area 2 (oral toxicity in experimental animals) in 2,329 hits from PubMed and 
3,914 hits from Web of Science; for Area 3 (in vitro and in vivo genotoxicity and mode of action) in 
1,100 hits from PubMed and 2,290 hits from Web of Science; and for Area 4 (observations in humans) 
in 639 hits from PubMed and 1,073 from Web of Science. 
After removal of the duplicates, the total number of hits for Area 1 was 3,184, for Area 2 was 4,883, 
for Area 3 was 2,588, and for Area 4 was 1,295. 
The evaluation of all retrieved references for relevance by screening the title and abstract (if available) 
and applying the eligibility criteria (inclusion/exclusion) as described by in the technical specifications 
(see Appendix A of this external report) for each subject Area (1-4) resulted in a total number of 
relevant references for Area 1 of 33, for Area 2 of 44, for Area 3 of 75 (including two relevant 
references located in the Area 2 literature search), and for Area 4 of 5. 
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Appendix A – Tables Regarding Eligibility Criteria as provided by EFSA in 
the technical specifications 
Table 1A: Eligibility criteria for the selection of studies in humans 
Study design 
In 
Cross-sectional studies 
Cohort studies 
Case-control studies (retrospective and nested) 
Case series/Case reports(c) 
Out 
Animal studies 
In vitro studies 
Study 
characteristics: 
In 
Any study duration 
Any number of subjects 
Out - 
Population 
In 
All populations groups, all ages, males and females 
Study location: all countries  
Out - 
Exposure/ 
intervention 
In 
All routes of exposure (dietary, dermal, inhalation, transplacental exposure) 
 
Studies in which levels of the following target compounds have been measured in human 
tissues (including by bioassays), 
 
OR 
 
Studies in which the total exposure to the following target compounds has been estimated(a) 
 
 furan 
 2-methylfuran  
 3-methylfuran 
Out Studies on compounds other than furan, 2-methylfuran and 3-methylfuran 
Specific outcome of 
interest 
In All endpoints, including hormone levels  
Out 
Studies on gene expression only 
Studies on drug metabolising enzyme activity/levels only 
Language In English 
Time In From 2004 onwards 
Publication type 
In 
Peer-reviewed primary research studies (i.e. studies generating new data) 
Systematic reviews, reviews  and meta-analyses(b) 
Out 
Expert opinions, editorials, and letters to the editor 
PhD Theses 
Extended abstracts, conference proceedings 
(a): Although these studies will not serve for the hazard characterisation, they are informative and serve as supporting 
information. 
(b): Systematic reviews, reviews and meta-analysis will be included and used as background information for the hazard 
characterisation.  
(c): Case series/case report studies will be included to inform the hazard identification.  
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Table 1B: Eligibility criteria for the toxicity in experimental animals 
Study design 
In 
Experimental animal studies (e.g. rats, mice, monkeys, guinea pig, mini pigs, rabbit, 
hamster, dog, cat, mink, pigs) 
 
Out 
Studies on transgenic animals 
Human studies 
In vitro studies 
Study 
characteristics: 
In 
Any study duration 
Any number of animals 
Out - 
Population 
In Any experimental animal study, all ages, males and females 
Out - 
Exposure/ 
intervention 
In 
Route of administration: Oral (feeding, gavage studies) 
 
Exposure regime: single or repeated administration 
 
Number of doses: any 
 
Compounds:  
 furan 
 2-methylfuran  
 3-methylfuran 
Out 
Route of administration: dermal, inhalation, subcutaneous, intraperitoneal, intramuscular 
Studies on compounds other than furan, 2-methylfuran and 3-methylfuran 
Specific outcome 
of interest 
In All endpoints  
Out 
Studies on enzyme induction only (e.g. CYP modulation) 
Studies on gene expression only 
Studies on co-administration of pro-carcinogens (CON A, DMBA, NKK) only 
Studies on -omics profiles 
Studies on the protective effects of certain substances against methyl/2-methyl/3-methyl 
toxicity 
Language In English 
Time In From 1990 onwards 
Publication type 
In 
Peer-reviewed primary research studies (i.e. studies generating new data) 
Systematic reviews, reviews  and meta-analyses(a) 
Out 
Expert opinions, editorials, and letters to the editor. 
PhD Theses 
Extended abstracts, conference proceedings 
(a): Systematic reviews, reviews and meta-analysis will be included and used as background information.  
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Table 1C: Eligibility criteria for the Toxicokinetics 
Study design 
In 
Experimental animal (e.g. rats, mice, monkeys, guinea pig, mini pigs, rabbit, hamster, dog, 
cat, mink, pigs), human and in vitro studies  
 
in relation to: 
 absorption 
 distribution 
 metabolism  
 excretion 
Out - 
Study 
characteristics: 
In 
Any study duration 
Any number of animals 
Out - 
Population 
In Any experimental animal (all ages, males and females), human or in vitro study 
Out - 
Exposure/ 
intervention 
In 
Route of administration: Oral (feeding, gavage studies), inhalation, subcutaneous, 
intraperitoneal, intramuscular 
 
Compounds:  
 furan 
 2-methylfuran  
 3-methylfuran  
 
Number of doses: any 
 
Exposure regime: single or repeated administration 
Out 
Dermal application  
Studies on compounds other than furan, 2-methylfuran and 3-methylfuran  
Specific outcome 
of interest 
In Any outcome in relation to absorption, distribution, metabolism and excretion  
Out - 
Language In English 
Time In From 1990 onwards 
Publication type 
In 
Peer-reviewed primary research studies (i.e. studies generating new data) 
Systematic reviews, reviews  and meta-analyses(a) 
Out 
Expert opinions, editorials, and letters to the editor. 
PhD Theses 
Extended abstracts, conference proceedings 
(a): Systematic reviews, reviews and meta-analysis will be included and used as background information.  
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Table 1D: Eligibility criteria for the genotoxicity and mode of action 
Study design 
In 
Experimental animal studies (e.g. rats, mice, monkeys, guinea pig, mini pigs, rabbit, 
hamster, dog, cat, mink, pigs) and in vitro studies  
 
In relation to: 
 genotoxicity,  
 mode of action 
Including studies on transgenic animals(a) 
 
Out - 
Study 
characteristics: 
In 
Any study duration 
Any number of animals 
Out - 
Population 
In Any experimental animal (all ages, males and females) or in vitro study 
Out - 
Exposure/ 
intervention 
In 
Route of administration: Oral (feeding, gavage studies), inhalation, subcutaneous, 
intraperitoneal, intramuscular. 
 
Compounds:  
 furan 
 2-methylfuran  
 3-methylfuran  
 
Number of doses: any 
 
Exposure regime: single or repeated administration 
 
Out 
Dermal application  
Studies on compounds other than furan, 2-methylfuran and 3-methylfuran   
Specific outcome 
of interest 
In Genotoxicity and mechanistic studies  
Out - 
Language In English 
Time In From 1990 onwards 
Publication type 
In 
Peer-reviewed primary research studies (i.e. studies generating new data) 
Systematic reviews, reviews  and meta-analyses(b) 
Out 
Expert opinions, editorials, and letters to the editor. 
PhD Theses 
Extended abstracts, conference proceedings 
(a): It is considered that studies on transgenic animals are helpful in terms of mechanism of action. 
(b): Systematic reviews, reviews and meta-analysis will be included and used as background information. These types of 
publications will not go through the data extraction process. 
 
  
ELS for furan and its methyl analogues 
 
 
 
www.efsa.europa.eu/publications 20 EFSA Supporting publication 2017:EN-1066 
The present document has been produced and adopted by the bodies identified above as authors. This task has been carried out exclusively by the authors in 
the context of a contract between the European Food Safety Authority and the authors, awarded following a tender procedure. The present document is 
published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The 
European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, 
without prejudice to the rights of the authors. 
 
 
 
Appendix B – Identified relevant references for each area 
 
AREA 1 
Reference list with all relevant references identified for AREA 1: Data on toxicokinetics (absorption, 
distribution, metabolism and excretion) in experimental animals and humans and from in vitro studies 
published in English since 1990. 
 
Becalski, A.T., A. M.; Cooke, G. M.; Gill, S. S., 2013. Investigation of possible endogenous formation 
of furan in Fischer-344 rat. Toxicological and Environmental Chemistry 95, 814-822. 
Brus, L.A.L., D.; Peterson, L. A., 2011. Oxidation of furan to a reactive metabolite by human 
cytochrome P450 enzymes. Abstr. Pap. Am. Chem. Soc. 242. 
Burka, L.T.W., K. D.; Irwin, R. D., 1991. Disposition of [14C]furan in the male F344 rat. Journal of 
toxicology and environmental health 34, 245-257. 
Chen, L.J.H., S. S.; Peterson, L. A., 1995. Identification of cis-2-butene-1,4-dial as a microsomal 
metabolite of furan. Chemical research in toxicology 8, 903-906. 
Chen, L.J.H., S. S.; Peterson, L. A., 1997. Characterization of amino acid and glutathione adducts of 
cis-2-butene-1,4-dial, a reactive metabolite of furan. Chemical research in toxicology 10, 866-874. 
Churchwell, M.I.S., R. C.; Von Tungeln, L. S.; Gamboa da Costa, G.; Beland, F. A.; Doerge, D. R., 
2015. Evaluation of serum and liver toxicokinetics for furan and liver DNA adduct formation in male 
Fischer 344 rats. Food and chemical toxicology : an international journal published for the British 
Industrial Biological Research Association 86, 1-8. 
Ferguson, L.J.H., S. S.; Peterson, L. A., 1996. Identification of cis-2-butene-1,4 dial as a furan 
metabolite and its reactions with biologically relevant molecules. Abstr. Pap. Am. Chem. Soc. 212, 
94-TOXI. 
Garle, M.J.F., J. R., 1990. Reactive metabolite formation catalysed by cytochrome P-450j. Toxicology 
in vitro : an international journal published in association with BIBRA 4, 493-496. 
Gates, L.A.L., D.; Peterson, L. A., 2012. Trapping of cis-2-butene-1,4-dial to measure furan 
metabolism in human liver microsomes by cytochrome P450 enzymes. Drug metabolism and 
disposition: the biological fate of chemicals 40, 596-601. 
Gates, L.A.P., M. B.; Matter, B. A.; Peterson, L. A., 2014. Comparative metabolism of furan in rodent 
and human cryopreserved hepatocytes. Drug metabolism and disposition: the biological fate of 
chemicals 42, 1132-1136. 
Grill, A.E.S., T.; Gates, L. A.; Lu, D.; Bandyopadhyay, D.; Yuan, J. M.; Murphy, S. E.; Peterson, L. A., 
2015. Abundant Rodent Furan-Derived Urinary Metabolites Are Associated with Tobacco Smoke 
Exposure in Humans. Chemical research in toxicology 28, 1508-1516. 
Hamberger, C.K., M.; Schauer, U. M.; Dekant, W.; Mally, A., 2010. Hepatobiliary toxicity of furan: 
identification of furan metabolites in bile of male f344/n rats. Drug metabolism and disposition: the 
biological fate of chemicals 38, 1698-1706. 
Jun, H.J.L., K. G.; Lee, Y. K.; Woo, G. J.; Park, Y. S.; Lee, S. J., 2008. Correlation of urinary furan with 
plasma gamma-glutamyltranspeptidase levels in healthy men and women. Food and chemical 
toxicology : an international journal published for the British Industrial Biological Research 
Association 46, 1753-1759. 
Kedderis, G.L., 1997. Extrapolation of in vitro enzyme induction data to humans in vivo. Chemico-
biological interactions 107, 109-121. 
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